{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=42",
    "query": {
      "condition": "Advanced Malignancy",
      "page": 42
    },
    "page_size": 10
  },
  "pagination": {
    "page": 42,
    "page_size": 10,
    "total_count": 9808,
    "total_pages": 981,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=43&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Malignancy&page=41&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T02:12:18.589Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02288507",
      "title": "Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatocellular Cancer"
      ],
      "interventions": [
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "yttrium-90 radioembolization",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Hawaii",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-11",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2019-11-08",
      "last_synced_at": "2026-11-02T02:12:18.589Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02288507"
    },
    {
      "nct_id": "NCT00129207",
      "title": "Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumors"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-02-11",
      "last_synced_at": "2026-11-02T02:12:18.589Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00129207"
    },
    {
      "nct_id": "NCT06206837",
      "title": "A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "vepdegestrant",
          "type": "DRUG"
        },
        {
          "name": "PF-07220060",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2024-02-19",
      "completion_date": "2027-05-25",
      "has_results": true,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-11-02T02:12:18.589Z",
      "location_count": 34,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 22 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06206837"
    },
    {
      "nct_id": "NCT06960395",
      "title": "Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor Malignancies",
        "EGFR Positive Solid Tumors",
        "EGFR"
      ],
      "interventions": [
        {
          "name": "VIR-5525",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vir Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 450,
      "start_date": "2025-07-22",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-11-02T02:12:18.589Z",
      "location_count": 2,
      "location_summary": "Scottsdale, Arizona • Houston, Texas",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06960395"
    },
    {
      "nct_id": "NCT00022477",
      "title": "BMS-247550 in Treating Patients With Recurrent or Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "BMS-247550",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2001-09",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2013-09-05",
      "last_synced_at": "2026-11-02T02:12:18.589Z",
      "location_count": 15,
      "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 10 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022477"
    },
    {
      "nct_id": "NCT03371381",
      "title": "An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of Lung"
      ],
      "interventions": [
        {
          "name": "JNJ-64041757",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2018-01-02",
      "completion_date": "2018-10-09",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-11-02T02:12:18.589Z",
      "location_count": 3,
      "location_summary": "Baltimore, Maryland • Nashville, Tennessee • Spokane, Washington",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03371381"
    },
    {
      "nct_id": "NCT03929029",
      "title": "Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab (480 mg infusion)",
          "type": "DRUG"
        },
        {
          "name": "NeoVax plus Montanide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2020-11-11",
      "completion_date": "2028-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-01-05",
      "last_synced_at": "2026-11-02T02:12:18.589Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03929029"
    },
    {
      "nct_id": "NCT00072631",
      "title": "Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Non Small Cell Lung Cancer",
        "Failed Prior Chemotherapy"
      ],
      "interventions": [
        {
          "name": "Tarceva (Trademark) (erlotinib HCl, OSI-774)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OSI Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2003-11-05",
      "completion_date": "2007-03-14",
      "has_results": false,
      "last_update_posted_date": "2018-02-08",
      "last_synced_at": "2026-11-02T02:12:18.589Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00072631"
    },
    {
      "nct_id": "NCT01859819",
      "title": "Treatment for Advanced B-Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large Cell Lymphoma",
        "Burkitt's Lymphoma",
        "High Grade B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "IT Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "31 Years",
        "sex": "ALL",
        "summary": "3 Years to 31 Years"
      },
      "enrollment_count": 45,
      "start_date": "2013-01",
      "completion_date": "2021-06",
      "has_results": false,
      "last_update_posted_date": "2022-10-25",
      "last_synced_at": "2026-11-02T02:12:18.589Z",
      "location_count": 5,
      "location_summary": "Buffalo, New York • Valhalla, New York • Charlotte, North Carolina + 2 more",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01859819"
    },
    {
      "nct_id": "NCT00669734",
      "title": "Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Pancreatic Adenocarcinoma",
        "Pancreatic Acinar Cell Carcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Stage III Pancreatic Cancer AJCC v6 and v7",
        "Stage IV Pancreatic Cancer AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Falimarev",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Inalimarev",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2010-02-01",
      "completion_date": "2027-04-21",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-11-02T02:12:18.589Z",
      "location_count": 1,
      "location_summary": "New Brunswick, New Jersey",
      "locations": [
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00669734"
    }
  ]
}